Humanigen Inc () CEO Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial.
Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’ (NIAID) Big Effect Trial (BET) in patients hospitalized with COVID-19.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE